| Sun Hee Kim, MD, MS | |
|
300 Pasteur Dr Rm S025, Stanford, CA 94305-2200 | |
| (650) 723-8284 | |
| (650) 725-7085 |
| Full Name | Sun Hee Kim |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 26 Years |
| Location | 300 Pasteur Dr Rm S025, Stanford, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083894844 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | A75251 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stanford Health Care | Stanford, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stanford Health Care | 6709797491 | 2572 |
News Archive
microDimensions launches a new version of its high precision whole slide alignment software Slidematch. With the new version users can align digital whole slide images from consecutive sections in brightfield and fluorescence mode, e.g. for the evaluation of the HER2 status of cancer patients.
New research at Wake Forest University School of Medicine evaluated the link between a common class of drugs used to prevent bone fractures in osteoporosis patients and the development of irregular heartbeat.
Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis.
› Verified 2 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
microDimensions launches a new version of its high precision whole slide alignment software Slidematch. With the new version users can align digital whole slide images from consecutive sections in brightfield and fluorescence mode, e.g. for the evaluation of the HER2 status of cancer patients.
New research at Wake Forest University School of Medicine evaluated the link between a common class of drugs used to prevent bone fractures in osteoporosis patients and the development of irregular heartbeat.
Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sun Hee Kim, MD, MS 300 Pasteur Dr Rm S025, Stanford, CA 94305-2200 Ph: (650) 723-8284 | Sun Hee Kim, MD, MS 300 Pasteur Dr Rm S025, Stanford, CA 94305-2200 Ph: (650) 723-8284 |
News Archive
microDimensions launches a new version of its high precision whole slide alignment software Slidematch. With the new version users can align digital whole slide images from consecutive sections in brightfield and fluorescence mode, e.g. for the evaluation of the HER2 status of cancer patients.
New research at Wake Forest University School of Medicine evaluated the link between a common class of drugs used to prevent bone fractures in osteoporosis patients and the development of irregular heartbeat.
Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis.
› Verified 2 days ago
Prista Charuworn, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 300 Pasteur Dr, Alway Build M211, Mc 5187, Stanford, CA 94305 Phone: 650-723-6661 | |
Yu Kuang Lai, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Andrea Lorenze, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Drive, Lane 154, Stanford, CA 94305 Phone: 650-723-6661 Fax: 650-498-6205 | |
Audra Horomanski, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 Fax: 650-498-6205 | |
Meghan Brady Marmor, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Lauren Michelle Ulsh, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Ann M Chen, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, A149, Mc5202, Stanford, CA 94305 Phone: 650-725-3376 Fax: 650-723-8305 |